AstraZeneca (LON:AZN)‘s stock had its “hold” rating reiterated by stock analysts at Liberum Capital in a report issued on Wednesday, ThisIsMoney.Co.Uk reports.
A number of other analysts have also commented on the company. Bryan, Garnier & Co reiterated a “neutral” rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Barclays set a GBX 7,600 ($99.31) price objective on AstraZeneca and gave the stock a “buy” rating in a research report on Friday, August 9th. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a research report on Friday, July 26th. Goldman Sachs Group lifted their price objective on AstraZeneca from GBX 5,000 ($65.33) to GBX 5,500 ($71.87) and gave the stock a “sell” rating in a research report on Monday, August 5th. Finally, Citigroup reiterated a “buy” rating and issued a GBX 7,000 ($91.47) price objective on shares of AstraZeneca in a research report on Monday, May 13th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus price target of GBX 6,688.24 ($87.39).
Shares of AZN stock opened at GBX 7,230 ($94.47) on Wednesday. The stock has a 50-day moving average price of GBX 6,755.80 and a 200 day moving average price of GBX 6,227.49. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. The firm has a market cap of $94.85 billion and a price-to-earnings ratio of 42.23. AstraZeneca has a 12 month low of GBX 5,312 ($69.41) and a 12 month high of GBX 7,349.30 ($96.03).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Diversification
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.